HCP Live
Contagion LiveCGT LiveNeurology LiveHCP LiveOncology LiveContemporary PediatricsContemporary OBGYNEndocrinology NetworkPractical CardiologyRheumatology Netowrk
  • MJHLS Brand Logo

© 2022 MJH Life Sciences™ , NeurologyLive – Clinical Neurology News and Neurology Expert Insights. All rights reserved.

ACC 2017: Late-Breaking Clinical Trials

Research includes safety of digoxin with atrial fibrillation, comparison of cerebral embolic protection devices, and cerebral microbleed triggers.

Presentations during the Late-Breaking Clinical Trials session at the American College of Cardiology’s Annual Scientific Sessions included a safety investigation of digoxin use in patients with atrial fibrillation, a study of two embolic protection devices and their abilities to prevent stroke and brain infarcts, and possible triggers of cerebral microbleeds during transacatheter aortic valve replacement.

slideshow image

ACC 2017: Late-Breaking Clinical Trials

slideshow image

Digoxin and Mortality in Patients with Atrial Fibrillation with and without Heart Failure: Does Serum Digoxin Concentration Matter? Abstract link.

slideshow image

Is digoxin use safe in patients with atrial fibrillation?

slideshow image

In patients with atrial fibrillation with and without heart failure, digoxin use was associated with increased mortality.

slideshow image

Cerebral Embolic Protection Devices During Surgical Aortic Valve Replacement: a Randomized Trial from the Cardiothoracic Surgical Trials Network. Abstract link.

slideshow image

Can two embolic protection devices prevent stroke and radiographic brain infarcts?

slideshow image

“. . .embolic protection device recipients were less likely to have larger infarcts. This may be important, as the risk of symptomatic stroke increases with infarct volume."

slideshow image

Silent Cerebral Microbleeds During TAVR: Insight from a Prospective Cerebral MRI Cohort. Abstract link.

slideshow image

Does transacatheter aortic valve replacement (TAVR) trigger cerebral microbleeds?

slideshow image

More and larger studies are needed to determine if microbleeding is caused by TAVR itself, anticoagulant use, or other factors.

PreviousNext